Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Chronic Kidney Disease Clear all
Terminated Phase 1 Interventional

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

NCT03840343
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
Interventions
Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

NCT00446459
View directory record Official record
Conditions
Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
Interventions
mycophenolate mofetil (CellCept)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Jul 22, 2026, 6:57 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

NCT03502031
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
Interventions
Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Drug
Lead sponsor
James A. Tumlin, MD
Other
Eligibility
75 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Lawrenceville, Georgia • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 22, 2026, 6:57 AM EDT
Enrolling by invitation Not applicable Interventional

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

NCT05514184
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions
PLAFOND diet
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Orange, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 22, 2026, 6:57 AM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product

NCT06790498
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Disease
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jul 22, 2026, 6:57 AM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Jul 22, 2026, 6:57 AM EDT
Recruiting No phase listed Observational

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

NCT01802034
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 22, 2026, 6:57 AM EDT
Not yet recruiting Phase 2 Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

NCT07594145
View directory record Official record
Conditions
Type 1 Diabetes, T1D Diabetic Chronic Kidney Disease, T1D Heart Failure, Cardio-renal Vascular Function and Failure
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 6:57 AM EDT
Terminated Phase 3 Interventional

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

NCT00120328
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
SPP301
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 80 Years
Enrollment
2,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Not applicable Interventional

Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit

NCT03470701
View directory record Official record
Conditions
Albuminuria, Chronic Kidney Diseases, Cardiovascular Diseases, Hypertension
Interventions
Mailed Urinalysis Smartphone Kit
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

NCT01053936
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Bardoxolone methyl (amorphous dispersion)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

NCT00800683
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 1356, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
24
States / cities
Phoenix, Arizona • Chula Vista, California • Riverside, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 22, 2026, 6:57 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

NCT07271186
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
ALN-ANG3, Evinacumab, ALN-ANG3 placebo, Evinacumab placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
57
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 6:57 AM EDT
Not listed Phase 3 Interventional

Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study

NCT01067950
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Isolated Pancreas Transplant, Intensive Insulin Therapy
Procedure · Drug
Lead sponsor
Nantes University Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Not applicable Interventional

Lifestyle Management of CKD in Obese Diabetic Patients

NCT02276742
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Chronic Kidney Disease (CKD)
Interventions
Social Cognitive Theory, Monitoring
Behavioral · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 1 Interventional

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

NCT04990427
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
CLBS201
Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 1 Interventional

Stem Cell Therapy for Chronic Kidney Disease

NCT04869761
View directory record Official record
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Drug
Lead sponsor
LaTonya J. Hickson
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

NCT00915200
View directory record Official record
Conditions
Diabetic Nephropathies, Proteinuria, Oxidative Stress
Interventions
N-acetylcysteine, silibin, high-dose silibin, N-acetylcysteine placebo, silibin placebo
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

NCT02540993
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
176
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 22, 2026, 6:57 AM EDT
Not yet recruiting Phase 4 Interventional

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

NCT07155694
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone 10 MG, Empagliflozin 10 MG
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

NCT02836574
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Renal Autologous Cell Therapy (REACT), Renal Biopsy
Biological · Procedure
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 22, 2026, 6:57 AM EDT
Terminated Not applicable Interventional Results available

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pioglitazone, Placebo, Nitroglycerin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Jul 22, 2026, 6:57 AM EDT
Completed Not applicable Interventional

Basic Needs Navigation Intervention to Address Multidimensional Adversity in African Americans With Diabetic Kidney Disease

NCT05357742
View directory record Official record
Conditions
Diabetic Nephropathies, Diabetes Mellitus, Type 2, Chronic Kidney Diseases, Healthy Lifestyle
Interventions
Individualized basic need navigation and lifestyle coaching and skills training, Enhanced usual care
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 22, 2026, 6:57 AM EDT